Zimbabwe has declined a substantial American healthcare agreement valued at $367m (£272m) over five years because of Washington's demand for confidential data.
The decision was revealed following a official document dated December was leaked, indicating that Head of State Emmerson Mnangagwa deemed the arrangement was "lopsided".
An official representative has since explained that the United States was requesting genetic material for scientific study and commercial gain but was unwilling to share the benefits from future vaccines.
"We will now turn to the difficult and regrettable process of scaling back our health assistance in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy said the US had provided more than $1.9bn as health assistance to Zimbabwe over the last twenty years.
A doctors' association in Zimbabwe has appealed for more dialogue to find a deal acceptable to both sides so the nation's vital HIV treatment initiative can continue.
Wider Background
This development comes after a comparable case in neighbouring Kenya, where a court halted a similar deal with the US following concerns were filed about the safety of Kenyans' medical information.
Since resuming the presidency last year, US President Donald Trump has drastically cut foreign aid and shut down the US Agency for International Development (USAID).
USAID had administered aid for the American government, but Trump claimed its expenditure was "inefficient" and his government was pursuing direct bilateral deals to boost transparency and accountability.
According to statements, 16 nations in Africa have so far agreed to similar agreements, constituting more than $18.3bn of fresh investment.
Details of the Declined Deal
The money for Zimbabwe would have funded "tackling HIV/Aids, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We believe this collaboration would have delivered extraordinary advantages for the people of Zimbabwe, particularly the 1.2 million currently on antiretroviral therapy through American-funded programmes," the Ambassador commented.
However, government spokesperson Nick Mangwana argued the proposed deal was "asymmetrical".
"Our nation was requested to share its genetic material and health information for a long time, without any equivalent guarantee of access to any scientific breakthroughs – like new medicines or tests – that might result from that provided information," Mangwana explained.
"In essence, our country would supply the raw materials for scientific discovery with no assurance that the resulting innovations would be accessible to our population should a future health crisis emerge."
National Interest and International Frameworks
Mangwana further pointed out that the US's withdrawal from the World Health Organization (WHO) and its push of one-on-one deals were upending structures previously set up via the international organization.
The spokesperson cited its Pandemic Benefit-Sharing scheme designed to manage potential global health emergencies.
"This framework is designed to ensure that when a nation contributes its information, the resulting advantages – including vaccines and treatments – are shared equitably, not monopolised exclusively by those with the capability to develop them."
The government's concerns over the US deal "should not be misconstrued as anti-American sentiment," he added.
"We welcome continued discussions with our US partners on how future collaboration could be arranged in a way that respects the sovereignty and interests of both nations."
Health Experts Reaction
Medical experts said it recognised the official position, but suggested that negotiations must proceed considering a large portion of the country's Aids initiatives relied on foreign aid.
"In cases where specific concerns exist, such as those involving information security or implementation frameworks, these can often be resolved via detailed discussion and mutually agreed protections," it added.
The halted deal emphasises the continuing debate between accepting crucial international aid and protecting national sovereignty in an ever more data-driven world.